Altered choline metabolism following PLCγ1 inhibition
Abstract :
Phosphoinositide-specific phospholipase C (PLC)γ1 is activated downstream of many receptor tyrosine kinases to promote cell motility. Inhibition of this protein is being explored as a therapeutic strategy for blocking cancer cell invasion and metastasis. The clinical development of such cytostatic therapies requires the implementation of pharmacodynamic biomarkers of target modulation. In this study we use magnetic resonance spectroscopy (MRS) to explore metabolic biomarkers of PLCγ1 downregulation in PC3LN3 prostate cancer cells. We show that inhibition of PLCγ1 via an inducible shRNA system or an inhibitory peptide causes a reduction in phosphocholine (PC) levels by up to 50% relative to the control as detected by This study reveals alterations in metabolism that accompany the cellular effects of PLCγ1 knockdown and highlights PC as a potential pharmacodynamic biomarker for monitoring the action of inhibitors targeting PLCγ1 signaling.
Introduction:
Tumorigenesis is a consequence of cumulative genetic aberrations affecting key signaling pathways that together with epigenetic events allow cells to establish a transformed phenotype. This is characterized by uncontrolled growth and proliferation, resistance to death signals and the ability to invade neighboring tissues . The final stage in cancer progression (metastasis to secondary sites) requires several distinct but interdependent steps: a) loss of cell-cell and cell-substratum adhesion, b) increased motility c) activation of extracellular proteases to enable degradation of basement membrane and surrounding extracellular matrix, d) invasion into local blood or lymphatic vessels e) survival during dissemination (requiring resistance to detachment-induced cell death -anoikis -and finally f) extravazation and colonization of distant organ sites where tumor cells establish a new blood supply, via neo-angiogenesis, to support independent growth . Invasion and metastasis are key hallmarks of aggressive tumors and lie at the root of most cancer deaths . It is thus unsurprising that major efforts in contemporary drug development are being devoted to blocking cancer cell invasion/metastasis and angiogenesis. One approach under investigation is direct targeting of signaling pathways that promote this process, for example the PLCγ1 cascade.
PLCγ1 is activated by phosphorylation downstream of many receptor tyrosine kinases including EGFR, VEGFR-2, c-MET, PDGFR, and also certain integrins to promote cell adhesion and motility as well as angiogenesis . Activated PLCγ1 catalyzes the breakdown of phosphatidylinositol (4,5) bisphosphate (PIP2) into inositol trisphosphate and diacylglycerol (DAG) which lead to the mobilization of Ca++ from intracellular stores and activation of protein kinase C respectively. This in turn triggers the release of actin binding proteins, sequestered by PIP2, resulting in cytoskeletal rearrangements at the leading edge necessary for cell motility .
The role of PLCγ1 in malignant growth is supported by several lines of evidence. Aberrant receptor tyrosine kinase signaling has been reported in a significant proportion of human cancers leading to activation of several downstream effector molecules including PLCγ1 .
Furthermore, deletion of the tumor suppressor PTEN, which encodes a lipid phosphatase, is the second most prevalent mutation in cancer after TP53 deletion and can lead to sustained activation of PLCγ1 signaling . PLCγ1 has also been reported to be overexpressed in some cancers including breast and colorectal carcinomas . In addition, upregulation of PLCγ1 expression can exert an anti-apoptotic role while inhibition of PLCγ1 activity with pharmacologic or genetic approaches is capable of halting tumor cell growth, invasion and dissemination to other sites .
PLCγ1 therefore represents an attractive target for rational drug development aimed at blocking cancer cell invasion and metastasis.
Contemporary drug development relies on the discovery and validation of pharmacodynamic biomarkers, particularly those that are minimally invasive, to aid in the assessment of treatment efficacy and correlating anti-tumour effects with target inhibition .
In this context, magnetic resonance spectroscopy (MRS) is one imaging modality that is gaining much interest. MRS is a powerful tool for monitoring tissue biochemistry as it allows the detection of several metabolites simultaneously and non-invasively in cells, animal models and patients.
MRS studies have shown that differences in choline metabolite profiles exist between normal and cancer tissues which may be useful as biomarkers for diagnosis and response In this study we investigate whether modulation of PLCγ1 could associated with metabolic alterations detectable by MRS that may be useful in future for monitoring novel therapies targeted at PLCγ1 signaling.
Our results show that inhibition of cell adhesion and migration in PC3LN3 human prostate carcinoma cells with a PLCγ1 inhibitory peptide or inducible shRNA knockdown of PLCγ1 is associated with decreased cellular PC content. This highlights PC as a potential biomarker of PLCγ1 inhibition.
Materials & Methods:
Cell culture: In house generated PC3LN3 human prostate carcinoma cells were derived from lymph node metastases of male NCr male mice bearing PC3 orthotopic prostate tumors . Cells were grown in RPMI-1640 medium containing 10% (v/v) heat-inactivated fetal calf serum (Life Technologies, Paisley; UK), maintained at 37°C in a 5% CO 2 humidified atmosphere and supplemented with fresh growth media three times per week. Western blotting: Western blot analysis for levels of PLCγ1 expression was performed using standard protocols as described previously . The primary antibodies used were mouse PLCγ1 (Santa Cruz Biotechnology, Inc. Santa Cruz, CA), rabbit PLCγ2 (Cell signaling Technology, Danvers; MA, USA), and mouse GAPDH (Abcam Ltd, Cambridge; MA, USA). The secondary anti-rabbit and anti-mouse antibodies used to detect these as well as the chemiluminescence reagents were purchased from Amersham Biosciences (Buckinghamshire, UK).
Migration assays:
Cell migration towards 5% fetal calf serum was analyzed using the Statistical analysis: All data are expressed as mean ± standard error and represent 3 or more independent repeats. Statistical significance was tested using an unpaired two-tailed student's t-test with p values ≤ 0.05 considered to be significant.
Results:
Inducible knockdown of PLCγ1 reduces cell adhesion and migration and alters cell choline phospholipid metabolism: As previously shown in this system , dox treatment led to a time-dependent reduction in levels of PLCγ1 that reached maximum knockdown (down to approximately 10% of controls) by day 14 ( Figure 1A ) while levels of PLCγ2 remained unchanged. In addition, and as previously documented phosphorylated levels of PLCγ1 were also reduced to the same extent thus confirming inhibition of PLCγ1 activity.
These effects resulted in reduced cell migration towards 5% fetal calf serum to 50%, on average, relative to the control clones. PLCγ1 knockdown cells adopted a rounded 
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P MRS also showed a reduction in PC levels from 14.4±1.7 fmol/cell, on average, in the control clones to 4.4±0.6 fmol/cell in the knockdown clones (p=0.002).
Nucleoside-triphosphate (NTP) levels also decreased by half in the knockdown clones relative to the controls (5.8±0.6 fmol/cell vs 2.6±0.4 fmol/cell, p=0.002) while no significant alterations were recorded in the other detectable metabolites including PE, GPC and GPE (Table 1) .
Analysis by 1 H MRS of the lipid fraction of cell extracts revealed no significant changes in levels of PtdCho (3.9±0.6 au/cell vs 3.6±0.6 au/cell) or the -CH2 (52±3 au/cell vs 47±1 au/ cell) or -CH3 (30±10 au/cell vs 26±7 au/cell) groups in control versus PLCγ1 knockdown cells respectively (p≥0.24).
Peptide-mediated inhibition of PLCγ1 reduces cell migration and alters cell choline phospholipid metabolism:
We also evaluated the inhibition of PLCγ1 signaling by a different means; namely using an inhibitory peptide. Following exposure of parental PC3LN3 cells to 10 µM Myr-peptide, a concentration previously shown to inhibit PLCγ1 by up to 75% , there was no significant change in cell counts (97±6% of controls) suggesting that cell proliferation was not significantly compromised. Cell migration towards 5% fetal calf serum was, however, significantly impaired and decreased to 31±6% relative to vehicle-treated controls (n=3, p=0.004) as shown in Figure 2A .
P MRS
analysis showed a decrease in PC levels to 78±2% relative to the control (n=4, p=0.011)) while levels of the other 31 P containing metabolites PE, GPC, GPE and NTP were not significantly changed as shown in Figure 2B .
Constitutive knockdown of PLCγ1 has no effect on cell adhesion or metabolism: The PC3LN3 clones with constitutive PLCγ1 knockdown showed reduced PLCγ1 expression to about 90% of controls ( Figure 3A) . Inhibition of chemotactic migration towards 5% fetal calf serum ranging from 49-73% (p<0.01) relative to the control clones was also recorded (data not shown).
Unlike cells with inducible PLCγ1 knockdown, cells with constitutive downregulation of
PLCγ1 showed concomitant up-regulation of PLCγ2 expression. Furthermore, the knockdown clones did not exhibit a rounded morphology and cell adhesion was not compromised. Analysis of cell metabolism by 1 H MRS showed that, interestingly (and despite decreased PLCγ1 protein expression), there were no significant differences in levels of PC, GPC or total choline between the PLCγ1 knockdown and the control cells ( Figure   3B & C). This result was also confirmed by 31 P MRS analysis where no significant alterations were recorded in levels of PC, PE, GPC, GPE or NTP as summarized in Table   1 . Analysis of lipid metabolites showed no significant changes in the 1 H spectra of control vs knockdown clones (data not shown).
Discussion:
Increased cell motility and invasion is a key requirement for the establishment of the aggressive metastatic tumor phenotype and signaling pathways that promote this trait are now considered potential targets for rational anti-cancer drug development . signaling is central to cell adhesion, motility and angiogenesis. This pathway is activated in many types of cancers either by overexpression of PLCγ1 or by activation/mutation of upstream growth factor receptors such as EGFR, c-MET, PDGFR, TRKB in cancer cells or activation of VEGFR2 in proliferating endothelial cells .
In this study we used RNA interference and an inhibitory peptide to downregulate PLCγ1 activity in human PC3LN3 prostate cancer cells, and 1 H and 31 P MRS to monitor metabolic alterations that may be useful as biomarkers to report on target inhibition.
In our system, knockdown of PLCγ1 protein expression by an inducible shRNA sequence correlated with decreased cell adhesion and migration towards 5% FCS as we have previously shown . These effects were accompanied by decreases in PC, total choline and NTP. No significant changes were recorded in the 1 H detectable lipid metabolites of PLCγ1 knockdown clones indicating that PLCγ1 knockdown had no major effects on overall lipid membrane composition.
To determine whether the effects observed following inducible knockdown of PLCγ1 were related to inhibition of its catalytic activity or other consequences such as loss of its membrane scaffolding function, we exposed parental PC3LN3 cells to a peptide that has previously been shown to effectively inhibit PLCγ1 activity . This caused a reduction in cell migration towards 5% FCS together with a fall in PC content as shown by 31 P MRS analysis.
However the peptide treatment could only partially recapitulate the fall in PC induced by PLCγ1 knockdown (85% vs 50%) indicating that the effects on PC levels observed with inducible shRNA were probably linked to both loss of PLCγ1 membrane scaffolding function and enzyme activity.
We further assessed the impact of PLCγ1 knockdown using stably expressed shRNA.
Similarly to the inducible shRNA expression system, constitutive knockdown of PLCγ1 mRNA and protein levels was associated with decreased cell migration towards 5% FCS.
However, in this system cell adhesion defects observed with inducible PLCγ1 knockdown were no longer apparent. Furthermore, expression of PLCγ2 was induced in PLCγ1 knockdown cells suggesting that this may be a compensatory or adaptive response to allow cells constitutively lacking PLCγ1 function to survive and proliferate. Interestingly, the absence of a phenotypic effect of PLCγ1 downregulation in this system was associated with no significant changes in choline metabolites.
This observation reinforces our hypothesis that the changes in choline metabolism recorded with the inducible system may be correlated with the loss of adhesion in response to PLCγ1 inhibition. This is of particular interest since previous studies have linked changes in choline metabolite profiles to malignant progression in cancer cells. In breast, ovarian and prostate carcinoma cells stepwise increases in cellular PC content and the PC/GPC ratio were observed in cell lines with increasing malignant potential . An increase in total cholinecontaining compounds and the PC/GPC ratio was also reported in a highly metastatic murine breast tumor model relative to its less metastatic counterpart . Furthermore, inhibition of cancer cell invasion with the anti-inflammatory agent indomethacin induced changes in choline metabolism similar in profile to those seen in cells with decreased invasiveness, namely reduced PC and increased GPC .
Our findings suggest that these metabolic changes may be related, at least in part, to the changing adhesion properties of cancer cells as they become more invasive.
Thus, transient downregulation of PLCγ1 signaling, whether by inducible shRNA or an inhibitory peptide, causes alterations in choline metabolism leading to a reduction in PC and total choline levels. The de novo synthesis of PC occurs via the Kennedy pathway following the phosphorylation of choline by choline kinase. PC is then incorporated via a multistep process into phosphatidylcholine (PtdCho), which can be hydrolyzed via phospholipase A2 (PLA2), PtdCho-specific PLC or PLD to form fatty acids + GPC, PC +DAG or choline + phosphatidic acid respectively as reviewed . PC can also be formed through the hydrolysis of another membrane phospholipid; sphingomyelin via sphingomyelinase to form ceramide and PC .
Although a direct link between inositol-based and choline-based lipid metabolism is yet to be established, findings from a study by Schwarzer et al suggest that bacterial phosphatidylinositol-specific phospholipase C can lead to activation of sphingomyelinase with a subsequent rise in ceramide (and presumably PC) levels, activation of nuclear factor-κB signaling and increased cell adhesion. A more recent study has also shown a role for sphingomyelinase in inducing the expression of cell adhesion molecules . In contrast, another study has shown that sphingomyelinase can have the opposite effect by inducing cell detachment although a rise in ceramide levels was still present in the adherent cell population .
More work is needed to characterize the exact metabolic processes underlying the observed changes in PC levels following PLCγ1 knockdown-mediated loss of adhesion.
Comparisons between the inducible and the constitutive shRNA systems by DNA microarray analysis showed that inducible knockdown of PLCγ1 correlated with decreased expression of the guanine exchange factor Rap1GEF which was not seen following constitutive PLCγ1 depletion (data not shown). Knockdown of Rap1 mimicked the effect of reduced PLCγ1 levels on adhesion while re-expression of Rap1GEF was able to rescue the adhesion defects that followed PLCγ1 knockdown indicating a role for this protein in 
